Abstract
OBJECTIVES: To explore the effect and value of salbutamol and budesonide in the treatment of patients with acute attack of bronchial asthma. METHODS: Medical records of patients with acute attack of bronchial asthma treated in our hospital from February 2020 to March 2021 were retrospectively analyzed. Of them, 30 patients received salbutamol atomization inhalation treatment in addition to routine treatment such as cough relief, oxygen inhalation and asthma relief (Group-I), and 40 patients received routine treatment and budesonide and salbutamol atomization inhalation (Group-II). The time of symptom improvement, the improvement in pulmonary function indexes and in peripheral blood eosinophile (EOS) and IgE levels were retrospectively analyzed and compared between the two schemes. RESULTS: After the treatment, the average time of respiratory restriction, cough, shortness of breath and wheezing improvement in patients, treated with Group-II were lower than those in Group-I (P<0.05). Forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and peak expiratory flow (PEF) in Group-II were significantly higher than those in Group-I (P<0.05). Post treatment levels of EOS and IgE in peripheral blood of Group-II were significantly lower than those of Group-I (P<0.05). CONCLUSION: On the basis of routine treatment, budesonide combined with salbutamol atomization inhalation for the treatment of patients with acute attack of asthma can be more efficient in improving symptoms and pulmonary, function and promote the effective reduction of EOS and IgE levels in peripheral blood.